BioSpace News Archive

Business

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

Mr. Benedicto brings over 20 years of experience as a strategy consultant in life sciences, both in Europe and the United States.

January 25, 2018
·
3 min read
Business

Orexo: Full Year Report Incl. Q4 2017

Total net revenues SEK 191.0 million (184.7).

January 25, 2018
·
5 min read
Drug Development

Alligator Bioscience Contracts Theradex Oncology as Clinical CRO for the Upcoming ATOR-1015 Phase I Study

The study is expected to commence in the second half of 2018.

January 25, 2018
·
3 min read
Business

Synpromics Announces New Partnership with UCL to Develop Novel Gene Therapies for Blood-Based Disorders

This new partnership further expands Synpromics’ activities in the cell and gene therapy sector, as it builds on its strategy of establishing partnerships with leading academics in the UK to integrate its technology into the next generation of gene-based medicines.

January 25, 2018
·
4 min read
Business

Applied DNA Awarded Multi-Year Contract to Develop Molecular Tracking Systems for Legal Cannabis Worldwide

Applied DNA Sciences, Inc. today announced the signing of an initial two-year, $1 million contract with TheraCann International Benchmark Corporation.

January 25, 2018
·
6 min read
Business

Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business

Congenica today announced the appointment of its new Chief Executive Officer, David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK.

January 25, 2018
·
4 min read
Business

Enamine Expands Collaboration with UCSF to Explore Synthetically Feasible Chemical Space

Enamine today announced that it has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF).

January 25, 2018
·
2 min read
Synthon’s [vic-]Trastuzumab Duocarmazine (SYD985) Granted FDA Fast Track Designation For Pre-Treated HER2-Positive Metastatic Breast Cancer

This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease, or progressed during or after [ado-]trastuzumab emtansine treatment.

January 25, 2018
·
6 min read
Business

Dr. Reddy’s Q3 and 9M FY18 Financial Results

Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the third quarter and nine months ended December 31, 2017 under International Financial Reporting Standards (IFRS).

January 25, 2018
·
10 min read
RepliCel CEO Provides 2018 Shareholder Update

Replicel Life Sciences is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler.

January 25, 2018
·
9 min read